** Shares of telehealth firm Hims & Hers HIMS.N fall 9% to $37.2 premarket
** A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's LLY.N popular weight-loss drug Zepbound in the U.S
** The Outsourcing Facilities Association in October filed a lawsuit against the FDA over its decision to remove the drugs its shortage list, saying that it still remains in short supply
** HIMS sells compounded versions of Novo Nordisk's NOVOb.CO Wegovy and Ozempic, chemically known as semaglutide
** The ruling has "direct read-through to the pending semaglutide case which we also expect will go in the FDA's favor," says brokerage Citi
** HIMS shares have nearly tripled in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.